Australian Broker Call *Extra* Edition – Jan 25, 2021

This story features ANSARADA GROUP LIMITED, and other companies. For more info SHARE ANALYSIS: AND

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities.

In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.

One key difference is the *Extra* Edition will not be updated daily, but merely "regularly" depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.

Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena's team of journalists.

Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.

The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.

The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.

COMPANIES DISCUSSED IN THIS ISSUE

Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)

AND   ARX   FCL   GNC   HUB (2)   MND   MSB   PNV   PPH   TYR   UMG  

AND    ANSARADA GROUP LIMITED

Overnight Price: $1.23

Moelis rates ((AND)) as Initiation of coverage with Buy (1) –

Moelis initiates coverage of Ansarada with a Buy rating and a target price of $1.83.

Ansarada's cloud-based information governance platform allows secure document management and workflow for use across M&A, capital raising, governance and other internal processes.

The company's flagship VDR product is now complemented by governance and board products with application across the full information governance life cycle. Moelis considers Ansarada well placed to grow share across its addressable markets.

M&A activity will likely rebound in 2021 after contracting by circa -20% in 2020. Encouragingly, says the broker, the company boasts a proven track record and high win rate with more than 23,000 transactions facilitated over 15 years.

Moelis expects Ansarada to show strong growth over 2021 with M&A markets recovering and revenue diversifying across new and enhanced platform use cases.

This report was published on January 15, 2021.

Target price is $1.83 Current Price is $1.23 Difference: $0.6
If AND meets the Moelis target it will return approximately 49% (excluding dividends, fees and charges).
The company's fiscal year ends in June.

Forecast for FY21:

Moelis forecasts a full year FY21 dividend of 0.00 cents and EPS of minus 8.30 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 14.82.

Forecast for FY22:

Moelis forecasts a full year FY22 dividend of 0.00 cents and EPS of minus 6.10 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 20.16.

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

ARX    AROA BIOSURGERY LIMITED

Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $1.12

Bell Potter rates ((ARX)) as Buy (1) –

Bell Potter maintains its Buy rating with a price target of $2.

Aroa Biosurgery's distribution partner Tela Bio reported its preliminary fourth-quarter results, leaving Bell Potter impressed by its strong revenue growth of 13-17% for the quarter and 17-18% growth for 2020 versus last year.

The broker is very impressed with this level of growth for a period in which the hernia registry was down by circa -30%. Bell Potter views Aroa Biosurgery's ability to take market share as proof of Tela’s strong sales strategy and execution.

Some key catalysts to drive growth include Bravo clinical updates and Myriad clinical data.

This report was published on November January 18, 2021.

Target price is $2.00 Current Price is $1.12 Difference: $0.88
If ARX meets the Bell Potter target it will return approximately 79% (excluding dividends, fees and charges).
The company's fiscal year ends in March.

Forecast for FY21:

Bell Potter forecasts a full year FY21 dividend of 0.00 cents and EPS of minus 2.30 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 48.70.

Forecast for FY22:

Bell Potter forecasts a full year FY22 dividend of 0.00 cents and EPS of minus 1.60 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 70.00.

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

FCL    FINEOS CORPORATION HOLDINGS PLC

Cloud services – Overnight Price: $3.85

Moelis rates ((FCL)) as Buy (1) –

While covid continues to impact FY21 sales industry-wide, Moelis still expects Fineos Corp Holdings to deliver software sales growth (compounded annual growth rate) of circa 28% between FY21-23 led by contracted ramp-ups.

With insurers modernising their legacy systems, Moelis notes the company is well placed to leverage its leadership and capture share in a circa $US6bn addressable market for LA&H core systems software.

Moelis reinstates coverage with a Buy rating and a target price of $4.77.

This report was published on January 19, 2021.

Target price is $4.77 Current Price is $3.85 Difference: $0.92
If FCL meets the Moelis target it will return approximately 24% (excluding dividends, fees and charges).
Current consensus price target is $4.86, suggesting upside of 26.1%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY21:

Moelis forecasts a full year FY21 dividend of 0.00 cents and EPS of minus 2.97 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 129.54.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is -2.0, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.

Forecast for FY22:

Moelis forecasts a full year FY22 dividend of 0.00 cents and EPS of minus 7.93 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 48.57.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is -0.1, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.

This company reports in EUR. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.9
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

GNC    GRAINCORP LIMITED

Agriculture – Overnight Price: $4.18

Bell Potter rates ((GNC)) as Buy (1) –

In its latest winter harvest update, total receivals (up-country) for GrainCorp till January 12, 2021 were 12.8mt, up 273% versus last year. Summer cropping activity is likely to deliver 1-2mt. Bell Potter expects crop receipts for FY21 to finish at around 16.2mt.

Also, domestic price premiums which were a headwind for the past two years have contracted materially, the broker points out, and the premium today relative to US prices is at the lowest level since 2017.

The broker believes the tailwind likely to be generated from this global grain price dynamic for an export facing business is underestimated by consensus.

Buy rating is retained with a target price of $5.05.

This report was published on January 13, 2021.

Target price is $5.05 Current Price is $4.18 Difference: $0.87
If GNC meets the Bell Potter target it will return approximately 21% (excluding dividends, fees and charges).
Current consensus price target is $5.08, suggesting upside of 21.5%(ex-dividends)
The company's fiscal year ends in September.

Forecast for FY21:

Bell Potter forecasts a full year FY21 dividend of 18.00 cents and EPS of 33.50 cents.
At the last closing share price the estimated dividend yield is 4.31%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 12.48.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 26.2, implying annual growth of -82.5%.
Current consensus DPS estimate is 15.3, implying a prospective dividend yield of 3.7%.
Current consensus EPS estimate suggests the PER is 16.0.

Forecast for FY22:

Bell Potter forecasts a full year FY22 dividend of 8.00 cents and EPS of 12.60 cents.
At the last closing share price the estimated dividend yield is 1.91%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 33.17.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 27.1, implying annual growth of 3.4%.
Current consensus DPS estimate is 15.7, implying a prospective dividend yield of 3.8%.
Current consensus EPS estimate suggests the PER is 15.4.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

HUB    HUB24 LIMITED

Wealth Management & Investments – Overnight Price: $26.45

Goldman Sachs rates ((HUB)) as Buy (1) –

Following the completion of the purchase of the PARS business, Hub24 added $9.3bn of funds under administration (FuA) to its books, bringing the second-quarter total FuA to $31.3bn.

Goldman Sachs notes custody FuA increased 39% versus last year to $22.0bn led by record net custody flows of $1.7bn and strong market returns of $1.2bn in the quarter.

Looking ahead, the broker expects custody flows of $2.7bn in the second half and 6.4bn in FY22, aligning with Hub24’s previous guidance of a target FuA range of $28-32bn by FY22 before acquisitions.

Goldman Sachs maintains its Buy rating with the target price rising to $26.61 from $23.20.

This report was published on January 19, 2021.

Target price is $26.61 Current Price is $26.45 Difference: $0.16
If HUB meets the Goldman Sachs target it will return approximately 1% (excluding dividends, fees and charges).
Current consensus price target is $25.23, suggesting downside of -4.6%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY21:

Goldman Sachs forecasts a full year FY21 dividend of 13.00 cents and EPS of 29.00 cents.
At the last closing share price the estimated dividend yield is 0.49%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 91.21.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 29.9, implying annual growth of 124.8%.
Current consensus DPS estimate is 10.8, implying a prospective dividend yield of 0.4%.
Current consensus EPS estimate suggests the PER is 88.5.

Forecast for FY22:

Goldman Sachs forecasts a full year FY22 dividend of 22.00 cents and EPS of 47.00 cents.
At the last closing share price the estimated dividend yield is 0.83%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 56.28.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 46.6, implying annual growth of 55.9%.
Current consensus DPS estimate is 21.5, implying a prospective dividend yield of 0.8%.
Current consensus EPS estimate suggests the PER is 56.8.

Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

---

Shaw and Partners rates ((HUB)) as Buy (1) –

Hub24 announced its second-quarter funds under administration (FuA) results, ending the quarter at $22.0bn and outperforming Shaw and Partners' estimate of $20.8bn led by outsized net flows and favourable market movements.

Indicating a strong quarter and reflecting robust momentum in the core business, notes the broker, Hub24's net flows were up 36.7% versus last year and 26.4% quarter on quarter at a record $1.7bn.

Shaw and Partners highlights Hub24 continues to capture a material share of net flows in the platform space and a growing market share of FuA to 2.1% at June 2020.

The broker believes Hub24 will continue to secure net flows from out of favour bank-owned and non-independent platforms, reaching more than 4% share by FY23. Margins are also expected to improve meaningfully as the company scales up.

The Buy rating is unchanged with a target price of $24.50.

This report was published on January 20, 2021.

Target price is $24.50 Current Price is $26.45 Difference: minus $1.95 (current price is over target).
If HUB meets the Shaw and Partners target it will return approximately minus 7% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $25.23, suggesting downside of -4.6%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY21:

Shaw and Partners forecasts a full year FY21 dividend of 10.90 cents and EPS of 25.50 cents.
At the last closing share price the estimated dividend yield is 0.41%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 103.73.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 29.9, implying annual growth of 124.8%.
Current consensus DPS estimate is 10.8, implying a prospective dividend yield of 0.4%.
Current consensus EPS estimate suggests the PER is 88.5.

Forecast for FY22:

Shaw and Partners forecasts a full year FY22 dividend of 16.80 cents and EPS of 39.30 cents.
At the last closing share price the estimated dividend yield is 0.64%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 67.30.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 46.6, implying annual growth of 55.9%.
Current consensus DPS estimate is 21.5, implying a prospective dividend yield of 0.8%.
Current consensus EPS estimate suggests the PER is 56.8.

Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

MND    MONADELPHOUS GROUP LIMITED

Mining Sector Contracting – Overnight Price: $14.41

Bell Potter rates ((MND)) as Downgrade to Hold from Buy (3) –

Propelled by better commodity prices over the past six months, Monadelphous Group's share price has rallied strongly since bottoming in August. The company stands to benefit from any improvement seen in mining investment, asserts Bell Potter. 

Still, Monadelphous faces stiff competition from companies including Cimic Group ((CIM)), Civmec ((CVL)) and GR Engineering with Civmec in particular proving to be a strong competitor and winning work from Fortescue Metals Group ((FMG)) and Rio Tinto ((RIO)), the analyst highlights.

The broker revises down its earnings estimates by -5.6%, -0.2% and -5.4% across FY21-FY23 due to continued margin pressure and border closures.

Bell Potter moves to Hold from Buy with the target rising to $14.25 from $11.09.

This report was published on January 18, 2021.

Target price is $14.25 Current Price is $14.41 Difference: minus $0.16 (current price is over target).
If MND meets the Bell Potter target it will return approximately minus 1% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $11.91, suggesting downside of -17.3%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY21:

Bell Potter forecasts a full year FY21 dividend of 48.00 cents and EPS of 55.50 cents.
At the last closing share price the estimated dividend yield is 3.33%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 25.96.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 56.8, implying annual growth of 47.0%.
Current consensus DPS estimate is 41.1, implying a prospective dividend yield of 2.9%.
Current consensus EPS estimate suggests the PER is 25.4.

Forecast for FY22:

Bell Potter forecasts a full year FY22 dividend of 53.00 cents and EPS of 65.80 cents.
At the last closing share price the estimated dividend yield is 3.68%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 21.90.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 64.8, implying annual growth of 14.1%.
Current consensus DPS estimate is 45.9, implying a prospective dividend yield of 3.2%.
Current consensus EPS estimate suggests the PER is 22.2.

Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

MSB    MESOBLAST LIMITED

Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $2.43

Bell Potter rates ((MSB)) as Buy (1) –

Mesoblast presented data from its landmark 537 patient Phase 3 trial with rexlemestrocel-L (REX) showing a single dose led to a significant reduction in heart attack, strokes and cardiac death.

Mesoblast will meet with FDA to discuss the path forward and Bell Potter believes the company will likely be required to do a confirmatory phase 3 trial focused on class II patients.

The broker concludes with the key question is waiting to see whether the FDA will grant accelerated approval prior to this trial. 

Buy rating with a valuation of $5.10.

This report was published on January 19, 2021.

Target price is $5.10 Current Price is $2.43 Difference: $2.67
If MSB meets the Bell Potter target it will return approximately 110% (excluding dividends, fees and charges).
The company's fiscal year ends in June.

Forecast for FY21:

Bell Potter forecasts a full year FY21 dividend of 0.00 cents and EPS of minus 7.62 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 31.90.

Forecast for FY22:

Bell Potter forecasts a full year FY22 dividend of 0.00 cents and EPS of minus 32.91 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 7.38.

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

PNV    POLYNOVO LIMITED

Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $2.63

Bell Potter rates ((PNV)) as Hold (3) –

Hold rating is retained with the target falling to $2.90 from $3.20. Polynovo's trading update disappointed with first half sales growth of 31% well below Bell Potter's forecasts as well as management's expectations.

While impressive when seen against the backdrop of a covid impacted period, comments the analyst, sales were expected to double in FY21 versus FY20.

Given the uncertainty in patient volumes, management has tempered growth expectations for the second half. Adding fuel to fire, grant revenues from the BARDA trial have been slower due to trial delays and are expected to resume in the third quarter.

This report was published on January 13, 2021.

Target price is $2.90 Current Price is $2.63 Difference: $0.27
If PNV meets the Bell Potter target it will return approximately 10% (excluding dividends, fees and charges).
The company's fiscal year ends in June.

Forecast for FY21:

Bell Potter forecasts a full year FY21 dividend of 0.00 cents and EPS of minus 1.60 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 164.38.

Forecast for FY22:

Bell Potter forecasts a full year FY22 dividend of 0.00 cents and EPS of 1.70 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 154.71.

Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

PPH    PUSHPAY HOLDINGS LIMITED

Software & Services – Overnight Price: $1.47

Shaw and Partners rates ((PPH)) as Hold (3) –

Molly Matthews will be taking over as Pushpay Holdings' CEO from Bruce Gordon from March 1, 2021. Better processing volumes in December has led to the company lifting its FY21 operating income guidance by 3.5%.

Shaw and Partners has increased its FY21 operating income forecast by circa 2.5% to $58m. On FY22, the broker prefers to be cautious as far as revenue growth is concerned, given the covid led pull-forward of demand in FY21.

Hold recommendation is maintained with a lower target price of $2.05 (versus $2.16).

This report was published on January 13, 2021.

Target price is $2.05 Current Price is $1.47 Difference: $0.58
If PPH meets the Shaw and Partners target it will return approximately 39% (excluding dividends, fees and charges).
Current consensus price target is $1.11, suggesting downside of -24.5%(ex-dividends)
The company's fiscal year ends in March.

Forecast for FY21:

Shaw and Partners forecasts a full year FY21 dividend of 0.00 cents and EPS of 4.89 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 30.09.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 3.3, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 44.5.

Forecast for FY22:

Shaw and Partners forecasts a full year FY22 dividend of 0.00 cents and EPS of 5.75 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 25.57.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 4.3, implying annual growth of 30.3%.
Current consensus DPS estimate is 2.0, implying a prospective dividend yield of 1.4%.
Current consensus EPS estimate suggests the PER is 34.2.

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

TYR    TYRO PAYMENTS LIMITED

Business & Consumer Credit – Overnight Price: $2.54

Goldman Sachs rates ((TYR)) as Neutral (3) –

Tyro Payments disclosed first half total transaction volume (TTV) of $12,118m, 3.7% ahead of Goldman Sachs' previous forecast of $11,065m. Also, the company has recently been experiencing connectivity issues that have impacted 30% of its merchant base.

While the revenue impact is expected to be immaterial, the issue will adversely affect customer churn, new customer growth and loss of partnerships, points out the broker, and will thus be slowing future growth.

Goldman Sachs maintains its Neutral rating with the target price falling to $3.15 from $3.65. 

This report was published on January 13, 2021.

Target price is $3.15 Current Price is $2.54 Difference: $0.61
If TYR meets the Goldman Sachs target it will return approximately 24% (excluding dividends, fees and charges).
Current consensus price target is $3.85, suggesting upside of 51.6%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY21:

Goldman Sachs forecasts a full year FY21 dividend of 0.00 cents and EPS of minus 4.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 63.50.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is -3.6, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.

Forecast for FY22:

Goldman Sachs forecasts a full year FY22 dividend of 0.00 cents and EPS of minus 2.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 127.00.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is -0.6, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.

Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

UMG    UNITED MALT GROUP LIMITED

Agriculture – Overnight Price: $4.01

Bell Potter rates ((UMG)) as Hold (3) –

According to the Brewers Association, the December quarter on-premise consumption trends are likely to be comparable to the June quarter, rather than the September quarter recovery.

While volume growth in 2021 is forecast at 6-7%, it is still below 2019 levels and unlikely to catch up until 2022. Looking at the soft consumption trends, Bell Potter assumes a conservative recovery in craft malt volumes leading to net profit forecast downgrades of -4% in FY21 and -6% in FY22.

The Hold rating is maintained. Target price reduced to $4.50 from $4.85. 

The report was published on January 14, 2021.

Target price is $4.50 Current Price is $4.01 Difference: $0.49
If UMG meets the Bell Potter target it will return approximately 12% (excluding dividends, fees and charges).
Current consensus price target is $4.81, suggesting upside of 20.0%(ex-dividends)
The company's fiscal year ends in September.

Forecast for FY21:

Bell Potter forecasts a full year FY21 dividend of 11.00 cents and EPS of 18.60 cents.
At the last closing share price the estimated dividend yield is 2.74%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 21.56.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 20.1, implying annual growth of 19.6%.
Current consensus DPS estimate is 11.6, implying a prospective dividend yield of 2.9%.
Current consensus EPS estimate suggests the PER is 20.0.

Forecast for FY22:

Bell Potter forecasts a full year FY22 dividend of 14.00 cents and EPS of 23.80 cents.
At the last closing share price the estimated dividend yield is 3.49%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.85.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 26.9, implying annual growth of 33.8%.
Current consensus DPS estimate is 16.1, implying a prospective dividend yield of 4.0%.
Current consensus EPS estimate suggests the PER is 14.9.

Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

---

Disclaimer:
The content of this information does in no way reflect the opinions of FNArena, or of its journalists. In fact we don't have any opinion about the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe and comment on. By doing so we believe we provide intelligent investors with a valuable tool that helps them in making up their own minds, reading market trends and getting a feel for what is happening beneath the surface. This document is provided for informational purposes only. It does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. FNArena employs very experienced journalists who base their work on information believed to be reliable and accurate, though no guarantee is given that the daily report is accurate or complete. Investors should contact their personal adviser before making any investment decision.

As part of emerging new trends overseas, The Australian Broker Call *Extra* Edition also includes providers of sponsored research. Readers should bear in mind, sponsored research, while not necessarily of lower quality, has the embedded complication that the company that is the subject of the research has paid for this research. Providers of sponsored research that can potentially be included in this Report are Breakaway Research, Edison Investment Research, Independent Investment Research, NDF Research, Pitt Street Research, and TMT Analytics.

Decisions about inclusions in this Report are made independently of the providers of stock market research and at full discretion of the team of journalists responsible for content at FNArena. Inclusion does not equal endorsement, in any way, shape or form. This Report is provided for informational purposes only.

Click to view our Glossary of Financial Terms